Introduction
Heart fatty acid binding protein (H-FABP) is a new marker with a low molecular weight which indicates early myocardial tissue injury (1, 2) . Various studies have shown that H-FABP becomes positive earlier than troponins and is more sensitive than myoglobin (3) (4) (5) . Besides, the H-FABP found in skeletal muscle is approximately 10-20% of the concentration of H-FABP in heart muscle (6) . Recently, we have observed 3 patients who had high creatinine kinase (CK) and H-FABP levels for various reasons.
Case 3
A 64 year-old female patient applied to the emergency room with complaints of atypical chest pain and extensive body pain. The values measured for the levels of H-FABP, CKMB and troponin I were 32 ng/ mL, 36 IU/L and l <0.2 ng/mL respectively. The patient was diagnosed with acute coronary syndrome and admitted to the coronary care unit. She was reported to have had a coronary bypass surgery in her history. She had been treated with atorvastatin for hyperlipidemia for the last 3 months. Her BP was 130/80 mmHg and pulse rate was 80/min. No pathological features were observed in her physical examination. The results of her ECG were within normal limits; her chest x-ray films revealed an increased heart shadow; and no localized wall motion abnormalities were observed with echocardiography. In her second measurement of cardiac enzymes performed on the same day, her CK was found as 1342 IU/L and troponin I as <0.2 ng/mL. It was concluded that with extensive body pain, the patient had high CK levels due to atorvastatin and this drug was withdrawn. Her current high H-FABP and CK levels were estimated to be associated with atorvastatin myopathy constructive effect. The patient was discharged and called for a follow-up visit after 2 weeks when it was observed that her high CK was back to normal and her H-FABP levels were negative. These results confirmed the idea that CK increased due to atorvastatin use, which, in turn, led to an increase in H-FABP levels.
Laboratory: CK and CKMB activity in serum was measured by the Olympus Chemistry Analyzer AU640. The dynamic range of this multiple-point rate test was calculated as 8.1% at 43 U/L. Point of Care Testing (POCT) systems were used for Troponin I assessments. Serum CK-MB ≥25 IU / L and Troponin I ≥0.2 ng/mL were considered as positive. The principle of the newly developed whole-blood rapid H-FABP test was based on a dual monoclonal antibody sandwich method using 2 distinct monoclonal antibodies and a gold label method. The rapid H-FABP test was calibrated to detect a serum H-FABP concentration of >6.2 ng/mL as a positive line, because other clinical investigations of this quantitative assay using the same monoclonal antibodies showed a cut-off level for diagnosing acute myocardial infarction (AMI) of 6.2 ng/mL (2, 5, 7-9).
Discussion
Cardiac troponins are highly sensitive and specific markers of myocardial damage (10, 11) . They are mainly found as structural proteins but they become detectable in the serum by 4 to 6 hours after myocardial injury (12) . In particular, early diagnosis is known to be extremely important in AMI. Thus, H-FABP has started to be used recently as a new cardiac marker which may increase at an earlier stage in AMI (1, 2) .
H-FABP is a new cardiac marker with a low molecular weight (15 kDa) that sensitively reveals myocardial injury (1) (2) (3) (4) (5) 13) . Its concentration in blood starts to increase in 1.5 hours and remains positive for nearly 24 hours. As a cytoplasmic protein, H-FABP plays a significant role in the intracellular transport of fatty acids for oxidation in mitochondria (14) . Being tissue-specific, it is named after the tissue of origin (Liver; L-FABP, Heart; H-FABP, Intestinal; I-FABP). It is most commonly found in the heart and liver. It is also known that the concentration of H-FABP in skeletal muscle is approximately 10-20% of its concentration in heart muscle (6) .
As a new marker, known to be more sensitive than troponins and myoglobin in diagnosing AMI in the first 2 hours,it has been recently started to be used. However, except for cardiac injury, what leads to high levels of H-FABP and what decreases its specificity are not clear. In our clinic, we detected high levels of H-FABP along with high levels of CK due to muscle destruction in the 3 cases reported above. The troponin I levels did not show any increase in these patients. We suggest that this protein, known to be present in muscle tissue, might increase as a result of muscle injury.
Conclusion
Consequently, physicians should be well aware that in patients who apply to emergency room with complaints of chest pain and had a diagnosis of high level of CK due to skeletal muscle destruction, as was the case with our patients, the H-FABP level might lead to false positive results and therefore, the level of troponin I should also be taken into consideration.
